Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years

Podobne zapisy

• Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD
  od: Suppli Ulrik, Charlotte
  Wydane: (2012)
• Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis
  od: Karabis, Andreas, i wsp.
  Wydane: (2013)
• Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials
  od: McGarvey, Lorcan, i wsp.
  Wydane: (2016)
• Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
  od: Ramos, Mafalda, i wsp.
  Wydane: (2016)
• Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study
  od: Wise, Robert A., i wsp.
  Wydane: (2018)